CalciMedica (CALC) Share-based Compensation (2019 - 2026)
CalciMedica's (CALC) quarterly Share-based Compensation came in at $4.1 million in Q1 2026, up 646.81% YoY from $549000.0 in Q1 2025, and up 559.16% on a QoQ basis from $622000.0 in Q4 2025.
CalciMedica (CALC) Share-based Compensation (2019 - 2026) Analysis & Trends
CalciMedica (CALC) has 8 years of Share-based Compensation data on file, last reported at $4.1 million in Q1 2026.
- Quarterly Share-based Compensation rose 646.81% year-over-year to $4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.1 million (up 162.32% YoY) and the FY2025 annual result came in at $4.6 million, down 2.13% from the prior year.
- Share-based Compensation climbed to $4.1 million in Q1 2026, from $622000.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $11.1 million in Q1 2023 to a low of -$32000.0 in Q4 2023.
- A 5-year average of $2.7 million and a median of $1.7 million in 2022 frame the typical range for Share-based Compensation.
- The widest YoY moves for Share-based Compensation: up 3221.19% in 2023, down 101.78% in 2023.
- Tracing CALC's Share-based Compensation over 5 years: stood at $1.8 million in 2022, then plunged by 101.78% to -$32000.0 in 2023, then soared by 2075.0% to $632000.0 in 2024, then fell by 1.58% to $622000.0 in 2025, then jumped by 559.16% to $4.1 million in 2026.
- The last three Share-based Compensation figures came in at $4.1 million (Q1 2026), $622000.0 (Q4 2025), and $5.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | - |
| 10 | CalciMedica | 9.71 Mn | -8.91 Mn | - | 316,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 316,000.00 |
| Jun 30, 2026 | 316,000.00 |
| Mar 31, 2026 | 4.10 Mn |
| Mar 31, 2026 | 4.10 Mn |
| Dec 31, 2025 | 622,000.00 |
| Dec 31, 2025 | 622,000.00 |
| Sep 30, 2025 | 5.00 Mn |
| Sep 30, 2025 | 5.00 Mn |
| Jun 30, 2025 | 5.60 Mn |
| Jun 30, 2025 | 5.60 Mn |
| Mar 31, 2025 | 549,000.00 |
| Mar 31, 2025 | 549,000.00 |
| Dec 31, 2024 | 632,000.00 |
| Dec 31, 2024 | 632,000.00 |
| Sep 30, 2024 | 5.00 Mn |
| Sep 30, 2024 | 5.00 Mn |
| Jun 30, 2024 | 3.60 Mn |
| Jun 30, 2024 | 3.60 Mn |
| Mar 31, 2024 | 414,000.00 |
| Mar 31, 2024 | 414,000.00 |